Celcuity's VIKTORIA-1 Phase 3 Trial Hits Primary Endpoint in Breast Cancer, Showing Clinically Meaningful PFS Improvement
CELC has more than doubled off its 52-week low of $9.51 on elevated volume (2.6× avg).
Summary
Celcuity announced positive topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 trial, achieving the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival (PFS). Both the gedatolisib triplet and doublet regimens demonstrated superiority over the comparator arm (alpelisib + fulvestrant) with manageable safety profiles. This positive outcome for the PIK3CA mutant cohort significantly expands the potential market for gedatolisib, complementing the previously announced FDA Priority Review for the PIK3CA wild-type cohort, as noted in the recent 10-K. The company intends to submit these new data as a supplemental New Drug Application (sNDA). This is a major de-risking event for Celcuity's lead drug candidate, validating its approach to targeting the PI3K/AKT/mTOR pathway. Investors will now focus on the detailed data presentation at the upcoming ASCO Annual Meeting and the subsequent sNDA submission, in addition to the existing PDUFA date of July 17, 2026, for the wild-type cohort.
At the time of this announcement, CELC was trading at $125.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $9.51 to $129.09. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.